Britain to study use of Lilly's weight loss drug to get people back to work
Britain will study whether the use of Eli Lilly's weight loss drug can get people back into work and help tackle the high rate of long-term sickness that has become a major drag on the economy. Health minister Wes Streeting predicted the use of the drug - a competitor to Novo Nordisk's Ozempic - could help transform the health of the nation,
UK eyes weight loss drug trials to get people back to work
Britain will study whether the use of Eli Lilly’s weight loss drug can get people back into work and help tackle the high rate of long-term sickness that has become a major
Eli Lilly to trial use of weight loss drugs to combat unemployment in U.K.
U.S. pharmaceutical giant Eli Lilly is exploring whether obesity drugs could be used to curb joblessness after signing a major investment deal with the U.K.
Can weight loss drugs get people back to work? Eli Lilly wants to find out
Eli Lilly (LLY) has partnered with the government of the United Kingdom to see if its blockbuster weight loss drug could help get some people back to work.
UK's Plan: Give the Unemployed Weight-Loss Drugs
The British government believes weight-loss drugs could play a role in its push to reduce the number of long-term unemployed people. The government says a $365 million investment from Eli Lilly will include a "major real-world study" on the effectiveness of tirzepatide,
Eli Lilly to invest $364M in UK trial linking obesity drug to employment
The company has committed £279 million ($364 million) to support national efforts aimed at reducing obesity, a critical health issue that also contributes to the UK’s high rates of economic inactivity.
Britain to study use of weight loss drug to get people back to work
Britain will study whether the use of Eli Lilly's weight loss drug can get people back into work and help tackle the high rate of long-term sickness that has become a major drag on the economy. Health minister Wes Streeting predicted the use of the drug - a competitor to Novo Nordisk's Ozempic - could help transform the health of the nation,
UK's weight loss jab Mounjaro might help people get back to work: All about it
The UK government starts a trial offering weight loss drug Mounjaro to unemployed obese individuals to improve health and workforce reentry. The initiative is part of a five-year NHS strategy. Eli Lilly commits £279 million to address Britain's health challenges,
UK plans weight loss drug trials to get people back to work
The UK plans to test US firm Eli Lilly' s weight loss jab Mounjaro to help the burden on the national healthcare system. Over a quarter of UK adults suffered from obesity in 2023 according to government data.
Could weight-loss drugs get people back to work? UK wants to find out
Studies show that people with obesity are more likely to find that ill health affects their productivity and attendance at work.
Could weight-loss drugs boost the economy?
Streeting announced a collaboration with the world's largest pharmaceutical company, Lilly, which will include a five-year trial investigating whether the use of the weight-loss d
Wes Streeting’s jabs are no panacea – my own experience of Mounjaro was miserable
It was the insistent questioning of my four-year-old grandson that goaded me into it. “Why is your tummy so big” he asked ...
Eli Lilly’s Zepbound to undergo first-of-its-kind study on economic impact
Eli Lilly (NYSE:LLY) has partnered with the British government to launch a first-of-its-kind real-world study to evaluate the ...
devdiscourse2d
Tirzepatide: A Potential Game-Changer in Tackling Long-Term Sickness
Britain is studying the use of Eli Lilly's weight loss drug, Tirzepatide, to address long-term sickness impacting its economy ...
Eli Lilly To Invest $364 Mln In UK's Biotech Segment To Tackle Health Challenges
Eli Lilly and Co. (LLY) is planning to invest $364 million or 279 million pounds in the biotechnology segment in the U.K., to ...
Lilly to Invest $364 Million in UK Biotech, Obesity Research
Eli Lilly & Co plans to invest £279 million ($364 million) in a new initiative to support UK biotechs along with a study of ...